PDAC has the worst outlook of any form of cancer in terms of progression-free and overall survival, and is the seventh most common cause of cancer related death worldwide. Around thirty percent of PDAC patients present as locally-advanced[1].
The first-line treatment options in this setting are mainly systemic chemotherapy such as FOLFIRINOX (FFX, a four-drug cocktail) or Gemcitabine + Nab-Paclitaxel (GN) combination therapy. Median overall survival (mOS) is less than 18 months with either regimen[2], representing a population with high unmet medical need.
External beam radiotherapy can be employed for those patients no longer responding to chemotherapy, however there is no strong clinical evidence of its effectiveness and this is thought to be due to the fact that only relatively low doses of radiation can be used due to the off-target effects on surrounding tissue structures.
ESMO international guidelines actively promote the development of new therapeutic options for this patient group. YntraDose is well placed to become the alternative treatment that is so urgently needed.